T cell dysfunction is a hallmark of many cancers, but the basis for T cell dysfunction and the
mechanisms by which antibody blockade of the inhibitory receptor PD-1 (anti-PD-1) …

Our current understanding of immunology was largely defined in laboratory mice, partly
because they are inbred and genetically homogeneous, can be genetically manipulated, allow …

Immunotherapy with PD-1 checkpoint blockade is effective in only a minority of patients with
cancer, suggesting that additional treatment strategies are needed. Here we use a pooled in …

Immune checkpoint blockade (ICB) results in durable disease control in a subset of patients
with advanced renal cell carcinoma (RCC), but mechanisms driving resistance are poorly …

Most patients with cancer either do not respond to immune checkpoint blockade or develop
resistance to it, often because of acquired mutations that impair antigen presentation. Here …

Large-scale high-throughput plant phenotyping (sometimes called phenomics) is becoming
increasingly important in plant biology and agriculture and is essential to cutting-edge plant …

Immune responses differ between laboratory mice and humans. Chronic infection with
viruses and parasites are common in humans, but are absent in laboratory mice, and thus …

Despite initial responses 1 , 2 – 3 , most melanoma patients develop resistance 4 to immune
checkpoint blockade (ICB). To understand the evolution of resistance, we studied 37 tumor …

Metastatic castration-resistant prostate cancer is typically lethal, exhibiting intrinsic or acquired
resistance to second-generation androgen-targeting therapies and minimal response to …

Sarcomatoid and rhabdoid (S/R) renal cell carcinoma (RCC) are highly aggressive tumors
with limited molecular and clinical characterization. Emerging evidence suggests immune …